Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study.

BACKGROUND In chronic kidney disease (CKD) arginine vasopressin (AVP) cannot efficiently act via renal V2-receptors. AVP is upregulated leading to augmented activation of V1a- and V1b-receptors, which might contribute to the increase in cardiovascular and infectious complications in CKD. Here, we evaluate copeptin, a surrogate of AVP, and its association with cause specific mortality among patients within the whole spectrum of renal function. METHODS Copeptin was measured in baseline samples from the LURIC (n = 3131 patients with coronary angiograms) and the 4D-Study (n = 1241 type 2 diabetic hemodialysis patients). Patients were stratified into 4 groups: estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m2, 60-89 mL/min/1.73 m2, <60 mL/min/1.73 m2, and hemodialysis. The association of copeptin with mortality was assessed by Cox proportional hazards regression during 9.9 years of median follow-up in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study and 4 years of median follow-up in the German Diabetes Dialysis Study (4D-Study). RESULTS Median copeptin increased with decreasing eGFR: 5.6 [interquartile range (IQR), 3.1-8.1] pmol/L (eGFR ≥90 mL/min/1.73 m2), 6.7 (2.9-10.5) pmol/L (eGFR 60-89 mL/min/1.73 m2), 15.3 (6.7-23.9) pmol/L (eGFR <60 mL/min/1.73 m2), and 80.8 (51.2-122) pmol/L (hemodialysis), respectively. Per SD increase in copeptin, the risk of coronary, infectious, and all-cause mortality increased by 25, 30, and 15% [hazard ratios (HR), 1.25; 95% CI, 1.13-1.39; HR, 1.30; 95% CI, 0.98-1.71; and HR, 1.15; 95% CI, 1.05-1.25], respectively, in patients with eGFR 60-89 mL/min/1.73 m2. Except for coronary death, results were similar among patients with more advanced renal disease. No significant association was found in patients with normal renal function. CONCLUSIONS Copeptin concentrations were independently associated with coronary, infectious, and all-cause mortality in patients with renal impairment. In patients with normal renal function no significant association was found.

[1]  H. Pavenstädt,et al.  Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction. , 2016, International journal of cardiology.

[2]  R. Lichtinghagen,et al.  Renal Function Interferes with Copeptin in Prediction of Major Adverse Cardiac Events in Patients Undergoing Vascular Surgery , 2015, PloS one.

[3]  M. Tonelli,et al.  Cause of Death in Patients with Reduced Kidney Function. , 2015, Journal of the American Society of Nephrology : JASN.

[4]  M. Petzold,et al.  High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease. , 2015, Clinical biochemistry.

[5]  B. Balkau,et al.  Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. , 2014, The Journal of clinical endocrinology and metabolism.

[6]  S. Sasaki,et al.  Lower serum sodium level predicts higher risk of infection-related hospitalization in maintenance hemodialysis patients: an observational cohort study , 2013, BMC Nephrology.

[7]  K. Rossing,et al.  Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. , 2013, International journal of cardiology.

[8]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[9]  C. Wanner,et al.  Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. , 2011, Journal of the American Society of Nephrology : JASN.

[10]  M. Christ-Crain,et al.  The stress hormone copeptin: a new prognostic biomarker in acute illness. , 2010, Swiss medical weekly.

[11]  D. Cook,et al.  Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock* , 2009, Critical care medicine.

[12]  N. Morgenthaler,et al.  The vasopressin and copeptin response to infection, severe sepsis, and septic shock* , 2009, Critical care medicine.

[13]  K. Walley,et al.  Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. , 2008, Resuscitation.

[14]  D. Annane,et al.  Metabolism modulators in sepsis: The abnormal pituitary response , 2007, Critical care medicine.

[15]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[16]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[17]  J. Struck,et al.  Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure , 2006, European journal of clinical investigation.

[18]  V. Wenzel,et al.  Serum vasopressin concentrations in critically ill patients* , 2006, Critical care medicine.

[19]  J. Struck,et al.  Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. , 2006, Clinical chemistry.

[20]  M. Gheorghiade,et al.  Vasopressin antagonism in heart failure. , 2005, Journal of the American College of Cardiology.

[21]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[22]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[23]  Lixia Zhao,et al.  Suppression of Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor-in Astrocytes by a V 1 Vasopressin Receptor Agonist : A cAMP Response Element-Binding Protein-Dependent Mechanism , 2004 .

[24]  K. Kikuchi,et al.  Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor , 1999, Molecular and Cellular Biochemistry.

[25]  A. Kurtz,et al.  Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  W. März,et al.  Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. , 2001, Pharmacogenomics.

[27]  H. Bruining,et al.  Vasopressin deficiency contributes to the vasodilation of septic shock. , 1998, Circulation.

[28]  I. Teitelbaum,et al.  Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. , 1995, The Journal of clinical investigation.

[29]  Michael V. Green,et al.  Coronary Vasoconstriction Induced by Vasopressin: Production of Myocardial Ischemia in Dogs by Constriction of Nondiseased Small Vessels , 1991, Circulation.